- Home
- DPRO vs FENC Comparison
DPRO vs FENC Comparison
Compare DPRO & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DPRO | FENC |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.8M | 230.8M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | DPRO | FENC |
|---|---|---|
| Price | $6.23 | $9.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $15.00 | $14.50 |
| AVG Volume (30 Days) | ★ 1.3M | 265.8K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | $158.69 | $65.12 |
| Revenue Next Year | $131.85 | $41.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.68 | $5.65 |
| 52 Week High | $14.37 | $10.27 |
Technical Indicators
Market Signals| Indicator | DPRO | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 77.37 |
| Support Level | $6.15 | $7.45 |
| Resistance Level | $6.74 | N/A |
| Average True Range (ATR) | 0.38 | 0.63 |
| MACD | 0.07 | 0.33 |
| Stochastic Oscillator | 98.37 | 90.97 |
Price Performance
Historical ComparisonAbout DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.